Pharmacokinetic Study on Three Formulations of Curcumin With Different Carriers

Inclusion Criteria: * Men or women between 18 and 50 years old (inclusive). * Body mass index between 18,5 and 34,9 at the selection visit (inclusive). * Normal to moderately high lipidemia (total cholesterol ≤ 240 mg / dl; LDL ≤ 160 mg / dl; Triglyceride ≤ 199 mg / dl). * Women of child bearing potential must accept to use an effective contraceptive method for the duration of the study. Exclusion Criteria: * Allergy to fish or seafood. * Special diet like a vegetarian or vegan diet. * Tobacco. * History of current or past alcohol and / or drug abuse. * Current or past performance athlete. * Malnutrition (assessed by albumin, hemoglobin and blood lipid levels). * People consuming omega 3 fatty acid or curcumin supplements for more than 6 months. * Medication affecting fat absorption (ie, Orlistat, Alli, etc.). * Medication which interferes with the metabolization of the medication (ie, anticoagulants like coumadin or warfarin, aspirin is not an exclusion criterion (Watson et al, 2009)) * Medication which affects lipid metabolism (ie, all types of drugs to lower cholesterol or triglycerides). * Medication which curcumin interacts with : angiotensin II blockers (losartan, valsartan), β-blockers (talinolol, celiprolol), calcium channels blockers (nifedipine), 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG CoA) reductase inhibitors (rosuvastatin), antineoplastic agents (docetaxel, etoposide, tamoxifen, everolimus, sirolimus), antibiotics (norfloxacin), antidepressant (midazolam), sulfonamides (sulfasalazine), antidiabetics (gliclazide). * Pregnant women or nursing women. * Menopause or pre-menopause with amenorrhea \> 6 months. * Systemic disease: vasculitis, Lupus Erythrocyte Disseminated (SLE), sarcoidosis, cancer (except if in remission for more than 10 years and without cerebral involvement), uncompensated hypothyroidism, vitamin B12 deficiency not supplemented and / or complicated, diabetes, severe renal insufficiency. * Abnormal liver, kidney or thyroid function; these conditions will not exclude a patient if he / she has been stabilized on treatment for at least 3 months and there has been no recent change in his / her medication. * Cardiac event or recent major surgery (\<6 months). * History of thrombosis or haemorrhagic diathesis. * Malabsorption disease such as pancreatitis, Crohn's disease or has had bariatric surgery. * Neurodegenerative disease (Parkinson disease). * Genetic disorder (Down syndrome). * Known psychiatric history: schizophrenia, psychotic disorders, major affective disorder (bipolar disorder and major depression \<5 years), panic disorder, Compulsive Obsessive Compulsive Disorder (OCD). * Neurological disorder (Epilepsy, cerebral trauma with loss of consciousness, subarachnoid hemorrhage). * Person who has donated blood or had significant blood loss in the 30 days prior to the start of the study. * Not available to perform the 3 treatments.